Desogestrel/Ethinyl Estradiol Shortage: What Providers and Prescribers Need to Know in 2026

Desogestrel/ethinyl estradiol is not on the FDA Drug Shortages Database as of 2026. It is widely manufactured by multiple companies under more than 25 brand names. Yet many providers continue to field calls from patients who cannot fill their prescriptions. This document addresses the reasons for these gaps, the clinical implications, and how you can streamline your practice's response.

Current Availability Status

No FDA-declared shortage exists for desogestrel/ethinyl estradiol tablets in 2026. The ASHP shortage tracker does not list this drug either. Supply is generally available at the wholesale level, with multiple manufacturers producing various formulation types:

Monophasic (0.15 mg/0.03 mg): Apri (Teva), Reclipsen (Warner Chilcott), Enskyce (Lupin), Emoquette (Afaxys), Desogen, Ortho-Cept, Isibloom, Juleber, Solia, Cyred, Cyred EQ -- most widely stocked.

Biphasic (0.15 mg DSG/0.02 mg EE + 0.01 mg EE tail): Kariva, Azurette, Mircette, Viorele, Kimidess, Pimtrea, Bekyree -- less widely stocked; some require special ordering.

Triphasic (0.1/0.125/0.15 mg DSG/0.025 mg EE): Cyclessa, Caziant, Cesia, Velivet -- lowest volume, may require ordering.

Why Patients Are Still Having Trouble Getting Filled

The root problem is not a supply shortage -- it is brand fragmentation and formulary misalignment. Here is what is driving patient callbacks to your practice:

Formulary-specific brand prescriptions: If you write for Apri and the patient's pharmacy does not stock it (or their insurance changed preferred brands), the pharmacist cannot fill it without a substitution authorization. Writing brand-neutral (e.g., 'desogestrel 0.15 mg/ethinyl estradiol 0.03 mg -- any equivalent generic') eliminates this barrier.

ACA formulary changes effective January 1: January is historically the highest-volume month for contraceptive fill problems, as insurance formulary changes take effect and patients encounter new preferred-brand requirements. Patient callbacks spike significantly in the first 6 weeks of each year.

Telehealth prescription volume: Online contraceptive platforms have substantially increased the volume of COC prescriptions being filled nationally. This drives up demand on specific high-volume generics and can cause temporary local depletions.

Clinical Guidance for Prescribers

To minimize patient callbacks and fill difficulties, consider the following practice changes:

Write generic, not brand-specific. Prescribe desogestrel/ethinyl estradiol by generic name and formulation type (monophasic, biphasic, triphasic) rather than by brand name. This allows pharmacists to substitute any available equivalent without callbacks.

Prescribe 90-day supplies when clinically appropriate. A 90-day supply reduces refill frequency by 67%, significantly lowering the number of times a patient encounters a local stock gap.

Have a backup pill documented in the chart. Document an acceptable alternative COC in each patient's chart (e.g., 'if desogestrel/EE unavailable, may substitute norgestimate/EE 0.25/0.035 mg monophasic'). This allows clinical staff to issue substitutions without a physician callback.

Know the formulation equivalence rules. Within the same formulation class, brands are interchangeable. Monophasic brands can substitute for one another. Biphasic (Kariva, Azurette) and triphasic (Cyclessa, Velivet) formulations are NOT interchangeable with monophasic brands without a new prescription.

Key Drug Interaction Reminders for Clinical Practice

When managing patients on desogestrel/ethinyl estradiol, be aware of these clinically significant interactions that may come up during intake:

Rifampin and enzyme-inducing anticonvulsants (carbamazepine, phenytoin, phenobarbital, oxcarbazepine): Significantly reduce COC efficacy. A non-hormonal method or high-dose progestin-only method should be considered.

Lamotrigine: COCs significantly reduce lamotrigine serum concentrations through induction of glucuronidation. Seizure control may be compromised. Lamotrigine dosing should be reassessed when starting or stopping COCs.

HCV combination regimens (ombitasvir/paritaprevir/ritonavir): Contraindicated with ethinyl estradiol-containing products due to risk of severe ALT elevation (>5x ULN). COC must be discontinued before starting this regimen and may be resumed approximately 2 weeks after completion.

Thyroid hormone replacement: COCs increase thyroid-binding globulin (TBG), which may require increased doses of thyroid hormone replacement. Monitor thyroid function tests and patient symptoms when COC use is initiated or discontinued.

39,049+ patients found their medications in stock

39K+

Find Desogestrel/Ethinyl Estradiol In Stock Today →

How medfinder Supports Your Patients

When patients call your practice unable to fill their prescription, medfinder for providers is a resource you can recommend. medfinder calls pharmacies in the patient's area to locate which ones can fill their prescription and texts the results directly to the patient -- eliminating the need for multiple follow-up calls to your office.

Related: How to help your patients find desogestrel/ethinyl estradiol | Patient-facing shortage update.